310 related articles for article (PubMed ID: 23784266)
1. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Mendell J; Zahir H; Matsushima N; Noveck R; Lee F; Chen S; Zhang G; Shi M
Am J Cardiovasc Drugs; 2013 Oct; 13(5):331-42. PubMed ID: 23784266
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
Mendell J; Noveck RJ; Shi M
J Cardiovasc Pharmacol; 2012 Oct; 60(4):335-41. PubMed ID: 23064240
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
5. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
7. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban: a focused review of its clinical pharmacology.
Lip GY; Agnelli G
Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
[TBL] [Abstract][Full Text] [Related]
9. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
10. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.
Corsini A; Ferri N; Proietti M; Boriani G
Drugs; 2020 Jul; 80(11):1065-1083. PubMed ID: 32504376
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
Krekels EH; Niebecker R; Karlsson MO; Miller R; Shimizu T; Karlsson KE; Ruff CT; Simonsson US; Jönsson S
Clin Pharmacokinet; 2016 Sep; 55(9):1079-90. PubMed ID: 26951208
[TBL] [Abstract][Full Text] [Related]
13. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Duchin K; Duggal A; Atiee GJ; Kidokoro M; Takatani T; Shipitofsky NL; He L; Zhang G; Kakkar T
Clin Pharmacokinet; 2018 Feb; 57(2):221-228. PubMed ID: 28512699
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.
Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
Clin Drug Investig; 2016 Feb; 36(2):127-36. PubMed ID: 26597179
[TBL] [Abstract][Full Text] [Related]
15. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults.
Mendell J; Chen S; He L; Desai M; Parasramupria DA
Clin Drug Investig; 2015 Jul; 35(7):447-53. PubMed ID: 26068927
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition.
Mikkaichi T; Yoshigae Y; Masumoto H; Imaoka T; Rozehnal V; Fischer T; Okudaira N; Izumi T
Drug Metab Dispos; 2014 Apr; 42(4):520-8. PubMed ID: 24459178
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
Parasrampuria DA; Truitt KE
Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
[TBL] [Abstract][Full Text] [Related]
19. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
[TBL] [Abstract][Full Text] [Related]
20. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Mikus G; Foerster KI; Schaumaeker M; Lehmann ML; Burhenne J; Haefeli WE
Clin Pharmacokinet; 2019 Sep; 58(9):1155-1163. PubMed ID: 30828771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
